|
| Agent | Description | Trial ID number | Phase | Design |
|
| Brivanib | Dual VEGFR2 and FGFR-1 | NCT01253668 | II | RCC patients after prior treatment with TKI or bevacizumab |
| Crizotinib | Alk and c-MET TKI | NCT01524926 | II | Patients with solid tumors |
| BIBF 120 | VEGFR 1–3 PDGFR and FGFR TKI | NCT01024920 | II | versus sunitinib in untreated mRCC patients |
| VEGF-Trap | Soluble decoy receptor; derivative of VEGFR1 | NCT00357760 | II | ccRCC patients after at least 1 prior treatment with TKI |
|
Ridaforolimus |
MTORC1 selective inhibitor | NCT01169532 | I | In combination with vorinostat in patients with solid tumors |
| NCT01295632 | I | In combination with MK2206 or γ-secretase inhibitor MK-0752 in patients with advanced solid tumors |
| MK-2206 | AKT inhibitor | NCT01239342 | II | Versus everolimus in refractory RCC patients |
| NVP-BEZ235 | Dual PI3K/mTOR inhibitor | NCT01482156 | I | In combination with everolimus in patients with advanced solid tumors |
| GDC-0980 | Dual PI3K/mTOR inhibitor | NCT01442090 | II | In comparison with everolimus in mRCC patients progressed on VEGF-targeted therapy |
| AMG-386 | Ang-1/2 inhibitor | NCT01548482 | II | In combination with temsirolimus in patients with advanced solid tumors |
| MDX-1203 | Anti-CD70 Ab-drug conjugate | NCT00944905 | I | Pretreated ccRCC or B-cell non-Hodgkin's lymphoma |
| MDX-1411 | Anti-CD70 Ab-drug conjugate | NCT00656734 | I | ccRCC pts treated with up to 6 prior systemic therapies |
| SGN-75 | Anti-CD70 Ab-drug conjugate | NCT01015911 | I | Pretreated ccRCC or B-cell non-Hodgkin's lymphoma |
| Girentuximab | Chimeric mAb cG250 | NCT00087022 | III | Adjuvant cG250 versus placebo in pts with ccRCC and high risk of recurrence |
| cG250-Lu177 | Lutetium-177 labeled cG250 | NCT00142415 | II | pts with advanced and progressive ccRCC |
| 90Y-cG250 | Yttrium-90 labeled cG250 | NCT00199875 | I | pts with advanced and progressive ccRCC |
| Panitumumab | Anti-EGFR mAb | NCT00425035 | II | mRCC pts naïve or after cytokine treatment |
| Vorinostat | HDAC inhibitor | NCT00278395 | II | mRCC pts naïve or after cytokine treatment |
| RO4929097 | γ-secretase/Notch inhibitor | NCT01141569 | II | ccRCC pts after anti-VEGF and/or mTOR inhibitor and/or immunotherapy failure |
| AS1411 | 26-mer DNA aptamer | NCT00740441 | II | ccRCC pts after at least 1 prior treatment with TKI |
|
